Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose combination drug containing three active ingredients: dexamethasone (a synthetic corticosteroid), neomycin (an aminoglycoside antibiotic), and polymyxin B (a polypeptide antibiotic). It is primarily used as an ophthalmic preparation to treat or prevent bacterial eye infections and to reduce associated inflammation. Dexamethasone suppresses the inflammatory response by inhibiting multiple inflammatory cytokines and mediators. Neomycin inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Polymyxin B disrupts the integrity of the bacterial cell membrane in susceptible Gram-negative bacteria. The combination provides both anti-inflammatory effects (from dexamethasone) and broad-spectrum antibacterial coverage (from neomycin and polymyxin B). It is indicated for steroid-responsive ocular conditions where there is a risk or presence of bacterial infection[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dexamethasone + neomycin + polymyxin B.